AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
A phase 3 trial of FPI-2265, Cabazitaxel, Abiraterone acetate in prostate cancer, run by AstraZeneca, now recruiting.
Overview
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) is a phase 3 interventional study registered as NCT07611110 by AstraZeneca, with 670 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-06-04. Interventions recorded: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Actinium-225.
- TrialTargeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares FPI-2265, AstraZeneca, Actinium-225, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
- AgentActinium-225 FPI-2068
Shares FPI-2265, AstraZeneca, Actinium-225.
- CollectionProstate Cancer Foundation (PCF)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
- TermAndrogen receptor pathway inhibitor (ARPI)
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.